W
CPRX

WealthCollab’s Catalyst Pharmaceutical CPRX Stock Holding History

WealthCollab’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11K Hold
349
– – ﹤0.01% 554
2026
Q1 		$8.64K Buy
349
+222
+175% +$5.29K ﹤0.01% 586
2025
Q4 		$2.96K Buy
127
+88
+226% +$1.96K ﹤0.01% 834
2025
Q3 		$769 Hold
39
– – ﹤0.01% 937
2025
Q2 		$847 Hold
39
– – ﹤0.01% 904
2025
Q1 		$946 Hold
39
– – ﹤0.01% 844
2024
Q4 		$814 Hold
39
– – ﹤0.01% 835
2024
Q3 		$776 Hold
39
– – ﹤0.01% 845
2024
Q2 		$605 Hold
39
– – ﹤0.01% 829
2024
Q1 		$622 Hold
39
– – ﹤0.01% 834
2023
Q4 		$656 Buy
+39
New +$533 ﹤0.01% 853

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

WealthCollab's CPRX Position: Q2 2026 in Review

WealthCollab held its Catalyst Pharmaceutical (CPRX) position steady in Q2 2026 at 349 shares worth $11K. The position accounts for ﹤0.01% of the portfolio, ranked #554.

WealthCollab first reported a position in CPRX in Q4 2023 and has held it in 11 quarters since. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • WealthCollab held 349 shares of Catalyst Pharmaceutical worth $11K as of Q2 2026.
  • WealthCollab left its Catalyst Pharmaceutical share count unchanged in Q2 2026.
  • Catalyst Pharmaceutical made up ﹤0.01% of WealthCollab's portfolio in Q2 2026, its #554 holding.
  • WealthCollab first reported a position in Catalyst Pharmaceutical in Q4 2023 and has held it in 11 quarters since.
  • 396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on WealthCollab's 13F filing for Q2 2026, filed 10 Aug 2026.